Humacyte (HUMA) Return on Equity (2021 - 2026)

Humacyte (HUMA) has 6 years of Return on Equity data on file, last reported at 0.17% in Q1 2026.

• Return on Equity for Q1 2026 came in at 0.17%, down 31.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.17% (down 31.0% YoY), and the FY2025 annual result was 0.05%, down 1.0% from the prior year.
• Return on Equity retreated to 0.17% in Q1 2026 per HUMA's latest filing, from 1.42% in the prior quarter.
• Over five years, Return on Equity peaked at 3.24% in Q3 2025 and troughed at 0.17% in Q1 2026.
• A 5-year average of 0.32% and a median of 0.01% in 2022 frame the typical range for Return on Equity.
• On a YoY basis, Return on Equity climbed as much as 321 bps in 2025 and fell as far as 109 bps in 2025.
• A 5-year view of Return on Equity shows it stood at 0.01% in 2022, then slumped by 435 bps to 0.04% in 2023, then soared by 151 bps to 0.02% in 2024, then soared by 6824 bps to 1.42% in 2025, then tumbled by 112 bps to 0.17% in 2026.
• Business Quant data shows HUMA's Return on Equity at 0.17% in Q1 2026, 1.42% in Q4 2025, and 3.24% in Q3 2025.